Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | HRH1 | P35367 | 5/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | DRD1 | P21728 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | HRH2 | P25021 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247744 | 0.94 | CACNA1G (0.48) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL4250707 | 0.88 | CACNA1G (0.50) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL4253374 | 0.88 | MALT1 (0.48) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL13994813 | 0.88 | MALT1 (0.47) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL5011575 | 0.88 | DRD3 (0.44) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL4245552 | 0.87 | HTR6 (0.47) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL5009526 | 0.85 | DRD2 (0.53) | DRD3DRD2HTR2ADRD4HTR1A | |
| SCHEMBL5011611 | 0.84 | ALDH1A1 (0.44) | DRD3KCNH2HRH1SLC6A2SLC6A4 | |
| SCHEMBL4248059 | 0.83 | DRD3 (0.41) | DRD3KCNH2HRH1CHRM2ADRA2A | |
| SCHEMBL3301407 | 0.83 | MEN1 (0.55) | DRD3CYP2D6DRD2USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | claimed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | claimed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | claimed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | claimed |
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | DRD3 680/4885KCNH2 31/4885HRH1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.